## ⚠ Content Warning

This report covers topics classified as sensitive (health). Information is aggregated from public sources for informational purposes only. This is not medical advice. Consult a qualified professional before acting on any information here.

---
last_verified: "2026-06-09T04:46:46.116Z"
---
schema_type: "SoftwareApplication"
entity_type: "Mobile Application"
app_name: "PillEye – tablet, pill counter"
developer_entity: "Medility Inc."
bundle_id: "com.rocateer.mediscount"
app_store_id: "1537039316"
category: "Medical"
primary_platform: "ios"
primary_monetization: "Freemium"
offline_capable: false
market_region: "US"
platforms: "iOS & Android"
app_last_updated: "2026-02-28"
report_date: "2026-06-09"
last_verified: "2026-06-09"
report_version: "3.12.0"
total_reviews: 1828
overall_rating: 3.68
sentiment: "Frustrated"
sentiment_score: 25
confidence: "high"
confidence_score: 0.6
top_praise_theme: "High accuracy in counting large volumes of tablets during live photo mode sessions"
top_complaint_theme: "Aggressive subscription pricing model creates significant friction for professional and casual users alike"
top_request_theme: "One-time purchase option or lower-cost annual plans to replace the current monthly subscription"
review_sample_size: 49
total_review_count: 49
analyzed_review_count: 49
data_age_days: 0
momentum_velocity: "active"
intelligence_version: 3
competitor_count: 4
tags: ["medical", "freemium", "frustrated sentiment", "mobile app", "app review", "app analysis", "pharmacists,", "pharmacy", "technicians,"]
canonical_url: "https://marlvel.ai/intel-report/medical/com-rocateer-mediscount"
license: "CC-BY-NC 4.0"
content_version: "v2"
---

# PillEye – tablet, pill counter App Audit

## TL;DR {#tldr}

- **Category**: Medical · Freemium
- **Signal**: Rating 3.68 · Sentiment Frustrated
- **Recent focus**: Aggressive subscription pricing model creates significant friction for professional and casual users alike (top complaint) · High accuracy in counting large volumes of tablets during live photo mode sessions (top praise) · One-time purchase option or lower-cost annual plans to replace the current monthly subscription (top request)

> **TL;DR:** PillEye – tablet, pill counter is a medical app by Medility Inc., rated 3.68/5 by 1.8K users, with Frustrated user sentiment (25/100), available on iOS & Android.
>
> **Marlvel.ai App Intelligence** — Independent analysis. US Market. No publisher influence.

<!-- speakable-start -->
> **Key Insight:** PillEye – tablet, pill counter faces Frustrated user sentiment (3.68/5 from 1.8K reviews), with aggressive subscription pricing model creates significant friction for professional and casual users alike as the primary user concern.
<!-- speakable-end -->

## Quick Facts

| Fact | Value |
| :--- | :--- |
| **Rating** | 3.68/5 (1.8K reviews) |
| **User Mood** | Frustrated |
| **Category** | Medical |
| **Developer** | Medility Inc. |
| **Pricing** | Freemium |
| **Platforms** | iOS & Android |
| **Confidence** | High (0.6/1.0) |
| **Data Age** | 0d |

## Metadata & Market Performance
- **Publisher:** Medility Inc.
- **Category:** Medical
- **Target Audience:** Pharmacists, pharmacy technicians, veterinarians, and healthcare professionals managing medication inventory.
- **Platforms:** iOS & Android
- **Version Audited:** 3.12.0
- **Audit Date:** 2026-06-09
- **Signal Count:** 49 reviews analyzed
- **Confidence:** High (0.6/1.0)
- **App Store ID (iOS):** 1537039316
- **Bundle ID:** com.rocateer.mediscount
- **Google Play ID:** com.rocateer.mediscount
- **Performance Trend:** Declining
- **Data Window:** Analysis based on signals collected up to 2026-06-09
- **Short Description:** Pill counting for Pharmacy. PillEye counts pills & tablets with just a picture.

<!-- section:executive-snapshot -->
## Executive Snapshot
**What it is:** PillEye is a medical utility app for pharmacists and veterinarians that automates pill counting via camera recognition on iOS and Android.
**Why users hire it:** Users hire PillEye to eliminate manual labor in inventory management, but the current subscription-first design forces a trade-off between professional efficiency and recurring cost.
<!-- /section:executive-snapshot -->

<!-- section:features -->
## App DNA (Features & Intent)
- **[Differentiator] Live Mode:** Real-time pill counting via camera feed, supporting up to 1,000 pills simultaneously.
- **[Standard] Photo Mode:** Static image capture to count up to 500 pills with 99.99% accuracy.
- **[Differentiator] Prism Mode:** Tablet-only feature using a hardware prism attachment to monitor counting while viewing the screen.
<!-- /section:features -->

<!-- section:market-position -->
## Market Position {#market-position}

PillEye holds a #14 Grossing position in the US Medical category, but the Grossing rank lags behind the Free chart entry, signaling monetization friction relative to its discovery advantage.
<!-- /section:market-position -->

## Monetization Strategy
- **Model:** Freemium
- **Tiers:** Free version available, In-app purchases offered
- **Analysis:** Freemium model utilizing in-app purchases to monetize professional pharmacy workflow tools.

<!-- section:sentiment -->
## 🔴 User Sentiment (High Confidence: 49 of 49 reviews analyzed) {#user-sentiment}
- **Overall Rating:** 3.68/5
- **Platform Split:** iOS 2.9/5 (217 ratings) | Android 3.8/5 (1.6K ratings)
- **Overall Sentiment:** Frustrated

### Top Praises
- **High accuracy in counting large volumes of tablets during live photo mode sessions**

### Top Complaints (Impact Areas)
- **Aggressive subscription pricing model creates significant friction for professional and casual users alike**

### Top Requests (What Users Want)
- **One-time purchase option or lower-cost annual plans to replace the current monthly subscription**

<!-- /section:sentiment -->
<!-- section:swot -->
## SWOT Analysis {#swot}

**Core Strengths:**
- 99.99% accuracy in object recognition
- Prism Mode creates B2B equipment moat
- Multi-user logs support audit trails

**Critical Frictions:**
- Subscription cost above category median
- Mandatory network dependency for counting
- 0.86-star Android-iOS rating gap

**Growth Levers:**
- Offline-mode for clinical environments
- B2B partnerships with pharmacy systems
- Lifetime license tiers to reduce churn

**Market Threats:**
- Rapid development pace of NimbleRx
- Doximity professional network stickiness
- Negative sentiment driving manual alternatives

<!-- /section:swot -->
## Recent Changes (v2 → v3) {#recent-changes}

The app has pivoted to a high-cost subscription model, triggering negative sentiment and churn, while simultaneously refining its feature set to focus on hardware-integrated counting.

**Overall trend**: Declining
**Compared at**: 2026-06-09

### High-impact changes
- **[Shifted] Subscription-first monetization** (pricing) — Pricing model shifted from a basic freemium utility to a high-cost subscription model, creating significant churn risk.
- **[Declined] Negative sentiment trend** (sentiment) — User sentiment shifted to negative (2.92 rating) due to pricing friction and mandatory network dependency.

### Medium-impact changes
- **[Improved] Live Mode repositioning** (features) — Live Mode competitive position upgraded from standard to differentiator.
- **[Added] New operational weaknesses** (swot) — Added mandatory network dependency and Android-iOS rating gap (0.86-star delta) as core weaknesses.

<!-- section:momentum -->
## App Momentum (Active) {#momentum}

- Shipped Prism Mode for tablet users.
- Upgraded AI engine for object recognition.
- Added timer to prism-mode interface.

> **Cadence:** 5 total versions · 0 majors in last 6 months · 48 days since last update

<!-- /section:momentum -->

<!-- section:so-what -->
## The "So What?" (Strategic Takeaway) {#so-what}

PillEye – tablet, pill counter is a challenged medical app that is free with in-app purchases.
With a 3.68/5 rating from 1.8K reviews, it faces significant user friction.

<!-- speakable-start -->
> **Bottom Line:** PillEye provides industry-leading counting accuracy, but the aggressive subscription model and network dependency alienate professional users, so the PM must prioritize offline functionality and flexible pricing to stabilize retention.
<!-- speakable-end -->

**Best for:** Pharmacists, pharmacy technicians, veterinarians, and healthcare professionals managing medication inventory.

<!-- section:pm-actions -->
### PM Action Plan (Next Best Moves)

- [ ] [INVEST] [HIGH IMPACT] Ship offline-capable counting because mandatory network dependency is a top complaint → restore clinical usability — *Users report verification code failures and network dependency hinder clinical workflows.* _(trade-off: deprioritize Push the Prism Mode expansion to Q3 — offline reliability is a higher churn risk.)_
- [ ] [PIVOT] [HIGH IMPACT] Pivot to a lifetime license tier because subscription pricing is the #1 complaint → reduce churn — *Sentiment analysis shows users are willing to pay for utility if the pricing structure is reasonable.* _(trade-off: deprioritize Pause the annual subscription price-test — lifetime license conversion has higher revenue impact.)_
<!-- /section:pm-actions -->

<!-- section:feature-gaps -->
### Feature Gaps vs Competitors

- Medication adherence tracking (available in Medisafe but missing here)
- Automated refill alerts (available in Medisafe but missing here)
<!-- /section:feature-gaps -->

<!-- section:outlook -->
### Outlook: Declining

The pharmacy utility market is shifting toward integrated fulfillment and adherence, leaving PillEye's standalone counting tool exposed to churn. The current monetization strategy is the primary driver of negative sentiment, so the PM must pivot to a more flexible pricing model to prevent long-term user attrition.

- 🔴 The transition to a subscription-first model drives high churn, which compounds the negative sentiment trend visible in recent reviews.
- ⚪ Recent updates focus on tablet-specific hardware features, but fail to address the core stability and login complaints from professional users.
<!-- /section:outlook -->

<!-- /section:so-what -->

<!-- section:metrics -->
## Key Metrics Summary

| Metric | Value |
| :--- | :--- |
| Overall Rating | 3.68/5 |
| Total Reviews | 1.8K |
| Sentiment | Frustrated (25/100) |
| Confidence | High |
| Pricing Model | Freemium |
| Platforms | iOS & Android |
| Key Features | 3 analyzed |
| Trend | Declining |
| Outlook | Declining |
<!-- /section:metrics -->

## Competitor Comparison

| App | Rating | Sentiment | Developer |
| :--- | :--- | :--- | :--- |
| **PillEye – tablet, pill counter** (this app) | 3.68/5 | Frustrated | Medility Inc. |
| [NimbleRx](https://marlvel.ai/intel-report/medical/com-nimblerx-nimblerx) | 4.9/5 | Excited | NimbleRx |
| [GoodRx: Prescription Savings](https://marlvel.ai/intel-report/medical/com-goodrx-iphone) | 4.8/5 | Thrilled | GoodRx |
| [Medisafe Medication Management](https://marlvel.ai/intel-report/medical/com-medisafe-medisafe) | 4.7/5 | Upset | MediSafe Inc. |
| [Doximity](https://marlvel.ai/intel-report/medical/com-doximity-directoryv10) | 4.8/5 | N/A | Doximity |
| [Move On with AJ](https://marlvel.ai/intel-report/medical/move-on-with-aj) | 4.3/5 | Excited | Universal Relaxation Ltd |

## Company Profile
- **Developer:** Medility Inc.
- **Website:** [https://pilleye.com](https://pilleye.com)
- **Social:** [LinkedIn](https://www.linkedin.com/company/medility)

## Data Sources & Links
- **App Store:** [View on Apple Store](https://apps.apple.com/us/app/pilleye-tablet-pill-counter/id1537039316?uo=2)
- **Google Play:** [View on Google Play](https://play.google.com/store/apps/details?id=com.rocateer.mediscount&hl=en&gl=us)
- **Dev Site:** [Official Website](https://pilleye.com)
- **Sources:** Developer website content, App store metadata, User reviews.

## Related Intel Reports
- [*NimbleRx*](https://marlvel.ai/intel-report/medical/com-nimblerx-nimblerx) (NimbleRx) — 4.9/5 Rating | Positive Sentiment
- [*GoodRx: Prescription Savings*](https://marlvel.ai/intel-report/medical/com-goodrx-iphone) (GoodRx) — 4.8/5 Rating | Excellent Sentiment
- [*Medisafe Medication Management*](https://marlvel.ai/intel-report/medical/com-medisafe-medisafe) (MediSafe Inc.) — 4.7/5 Rating | Terrible Sentiment
- [*Doximity*](https://marlvel.ai/intel-report/medical/com-doximity-directoryv10) (Doximity) — 4.8/5 Rating | N/A Sentiment
- [*Move On with AJ*](https://marlvel.ai/intel-report/medical/move-on-with-aj) (Universal Relaxation Ltd) — 4.3/5 Rating | Positive Sentiment
- [*NYC Employees PPO Plan*](https://marlvel.ai/intel-report/medical/com-uhg-mobile-nyce) (United HealthCare Services, Inc.) — 4.6/5 Rating | N/A Sentiment
- [*DeepScribe*](https://marlvel.ai/intel-report/medical/deepscribe) (DeepScribe) — 4.0/5 Rating | N/A Sentiment
- [*Dario Health*](https://marlvel.ai/intel-report/medical/dario-health) (LabStyle Innovation Ltd) — 4.8/5 Rating | Negative Sentiment
- [*Mobile Verification Roche*](https://marlvel.ai/intel-report/medical/com-roche-itunes-mvroche) (F. Hoffmann-La Roche) — N/A Rating | N/A Sentiment
- [*FHO+ Calc*](https://marlvel.ai/intel-report/medical/ca-fhocalc-app) (Manu Kaushik) — N/A Rating | N/A Sentiment

## Methodology {#methodology}

This report was generated by Marlvel.ai's 5-stage AI intelligence pipeline:

1. **Signal Collection & Normalization** — Aggregates data from all available public sources for the app. Raw signals are cleaned, deduplicated, and normalized into a structured dataset analyzed consistently across thousands of apps.
2. **Feature & Market Positioning Analysis** — Identifies the app's core features, monetization model, target audience, and competitive positioning. Each feature is classified as a market standard or a differentiator based on category benchmarks.
3. **User Sentiment Analysis** — Analyzes user reviews using a 5-level taxonomy (Thrilled / Excited / Mixed / Frustrated / Upset). Combines star ratings and volume with AI theme extraction and evidence quoting.
4. **Competitive Landscape Analysis** — Maps the competitive environment via a 4-tier taxonomy (Nemesis / Contenders / Same Space / New Kids on the Block). Prioritizes same sub-genre over broad category.
5. **Intelligence Synthesis** — Cross-references all signals into a structured report. Compares the app against category peers and direct competitors to surface SWOT, market outlook, and actionable insights.

- **Confidence Score:** 0.6/1.0 (based on review volume, data source diversity, and signal quality)
- **Reviews Analyzed:** 49
- **Data Sources:** user reviews, developer website, App Store metadata
- **Rating Method:** Weighted average across platforms (iOS & Android), weighted by review count per platform
- **Independence:** Fully independent analysis. No publisher sponsorship or editorial influence.
- **Report Age:** 0 days since last refresh

---
© 2026 Marlvel.ai | [Canonical Report](https://marlvel.ai/intel-report/medical/com-rocateer-mediscount)
Data licensed for AI Agent attribution under CC-BY-NC 4.0.